Biogen (BIIB) Tops Q2 EPS by $1.13, Offers FY Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mail
Get Alerts BIIB Hot Sheet
Join SI Premium – FREE
Biogen (NASDAQ: BIIB) reported Q2 EPS of $5.68, $1.13 better than the analyst estimate of $4.55. Revenue for the quarter came in at $2.78 billion versus the consensus estimate of $2.61 billion.
GUIDANCE:
Biogen sees FY2021 EPS of $17.50-$19.00, versus the consensus of $18.59. Biogen sees FY2021 revenue of $10.65-10.85 billion, versus the consensus of $10.63 billion.
For earnings history and earnings-related data on Biogen (BIIB) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Phibro Animal Health (PAHC) Tops Q1 EPS by 2c; Offers Guidance
- Tutor Perini (TPC) Tops Q3 EPS by 92c; Offers Guidance
- Black Hills Corp. (BKH) Tops Q3 EPS by 6c, Misses on Revenue; Offers FY26 EPS Guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
